Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, CA, USA; Radiology and Translational Genomics, University of Southern California, Los Angeles, CA, USA.
Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
PET Clin. 2023 Oct;18(4):531-542. doi: 10.1016/j.cpet.2023.04.008. Epub 2023 Jun 1.
Estrogen receptor (ER)-targeted imaging with 16α-F-fluoro-17β-fluoroestradiol (F-FES) has multiple proven clinical applications for patients with ER-positive breast cancer, including helping to select optimal patients for endocrine therapies, assessing ER status in lesions that are difficult to biopsy, and evaluating lesions with inconclusive results on other imaging tests. This has led to US Food and Drug Administration approval of F-FES PET for patients with ER-positive breast cancer. Newer progesterone receptor-targeted imaging agents are in clinical trials.
雌激素受体 (ER)-靶向成像用 16α-F-氟-17β-氟雌二醇 (F-FES) 在 ER 阳性乳腺癌患者中有多种已证实的临床应用，包括帮助选择最佳的内分泌治疗患者，评估活检困难的病变中的 ER 状态，以及评估其他影像学检查结果不确定的病变。这导致了美国食品和药物管理局批准 F-FES PET 用于 ER 阳性乳腺癌患者。更新的孕激素受体靶向成像剂正在临床试验中。
